BRAINEVER
LIVE

Serial Number

79188386

Owner

BRAINEVER

Attorney

Jeannine A Rittenhouse

Filing Date

Feb 12, 2016

Add to watchlist:

No watchlists yet
View on USPTO

BRAINEVER Trademark

Serial Number: 79188386 • Registration: 5220280

BRAINEVER is a trademark filed by BRAINEVER on February 12, 2016. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

BRAINEVER

74 rue du Faubourg Saint-Antoine
PARIS F75012 , FR

Entity Type: 99

Trademark Details

Filing Date

February 12, 2016

Registration Date

June 13, 2017

Published for Opposition

March 28, 2017

Cancellation Date

December 29, 2023

Goods & Services

Pharmaceutical products for the protection, the treatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilities, pharmaceutical compositions for the treatment of brain and spinal cord diseases or degenerative disorders; pharmaceutical products for the treatment of all cognitive deficiencies and neurodegenerative diseases; sanitary products for medical purposes, namely for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; chemo-pharmaceutical products for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; biological preparations for medical use, namely for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; chemical preparations for medical or pharmaceutical use, namely for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; diagnostic products for medical use, namely for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; medicines for human medicine for the treatment of all cognitive deficiencies, neurodegenerative diseases, brain and spinal cord diseases or degenerative disorders and for improving neurological abilities

Medical care services for neurodegenerative diseases; medical care for the treatment of brain diseases; surgical treatments of the brain and spinal cord; therapy services; diagnosing and evaluating individuals with Alzheimer's disease or any other cognitive deficiency

Surgical, medical apparatus and instruments for the prevention, treatment and repair of neurodegenerative diseases; testing apparatus used for the treatment of all cognitive deficiencies and neurodegenerative diseases and for the treatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilities

Research and development of pharmaceutical products; biotechnology research and development; scientific and technological services as well as research and design services relating to the development of treatments for neurodegenerative diseases; biological research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseases, and the treatment of brain and spinal cord diseases or degenerative disorders, bacteriological research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseases, and the treatment of brain and spinal cord diseases or degenerative disorders, chemical research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseases, and the treatment of brain and spinal cord diseases or degenerative disorders; medical and parapharmaceutical research in the field of the treatment of all cognitive deficiencies and neurodegenerative diseases, and the treatment of brain and spinal cord diseases or degenerative disorders; laboratory services and scientific research services particularly in the field of genetics; medical research in the field of brain diseases; technical information services relating to medical, pharmaceutical, parapharmaceutical and surgical activities; genetic research services; planning and development (design) of technical projects in the field of genetics; research and development in the field of medicine and genetics; scientific research and development services for the protection, treatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilities; design and development of procedures and techniques for the treatment of brain and spinal cord diseases and for improving neurological abilities; clinical trials of treatments for neurodegenerative diseases, brain or spinal cord diseases, cognitive deficiencies and degenerative disorders and of diagnostic methods in the field of these diseases and genetics

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
Sep 29, 2024 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Sep 6, 2024 INTS
INVALIDATION PROCESSED
Sep 6, 2024 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 30, 2024 INTR
CANCELLED SECTION 71
Dec 29, 2023 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 13, 2022 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 28, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 21, 2017 FICS
FINAL DISPOSITION PROCESSED
Sep 21, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 13, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 13, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 28, 2017 NPUB
PUBLISHED FOR OPPOSITION
Mar 28, 2017 PUBO
NOTIFICATION PROCESSED BY IB
Mar 25, 2017 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 8, 2017 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 8, 2017 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 8, 2017 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 21, 2017 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 9, 2017 CNSA
ASSIGNED TO EXAMINER
Feb 2, 2017 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 31, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 31, 2017 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 31, 2017 CHAN
ASSIGNED TO LIE
Jan 27, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 10, 2017 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 10, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 10, 2017 REAP
REFUSAL PROCESSED BY IB
Jul 29, 2016 RFNT
APPLICATION FILING RECEIPT MAILED
Jul 12, 2016 MAFR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 11, 2016 RFCS
REFUSAL PROCESSED BY MPU
Jul 11, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 9, 2016 RFCR
NON-FINAL ACTION WRITTEN
Jul 8, 2016 CNRT
ASSIGNED TO EXAMINER
Jul 8, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 8, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 7, 2016 REPR